We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01828528
Recruitment Status : Completed
First Posted : April 10, 2013
Last Update Posted : November 28, 2016
Sponsor:
Information provided by (Responsible Party):
Sheba Medical Center

Brief Summary:
The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery. The investigators also aim to study the short-term effect of bariatric surgery on gastric cholecystokinin levels before and 10 days after the bariatric surgery.

Condition or disease Intervention/treatment
Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Procedure: Sleeve gastrectomy

Study Type : Observational
Actual Enrollment : 26 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease and Cardiovascular Risk Utilizing Non-invasive Measures
Study Start Date : April 2013
Primary Completion Date : August 2016
Study Completion Date : August 2016


Group/Cohort Intervention/treatment
NAFLD after SG
26 patients with NAFLD undergoing sleeve gastrectomy (SG).
Procedure: Sleeve gastrectomy
An intra-operative liver biopsy was performed in 20 patients



Primary Outcome Measures :
  1. Change from baseline liver steatosis, steatohepatitis and fibrosis at different stages after bariatric surgery, measured by non-invasive measurements as described below. [ Time Frame: Baseline is defined as three weeks to one month before surgery. Different stages to compare to baseline are as following: 8-12 days and 12, 24 and 48 weeks after surgery. ]

    Measurements to be performed to assess liver disease stage at baseline and at 8-12 days and 12, 24 and 48 weeks after surgery:

    1. Blood tests of liver functions (Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase, gamma-glutamyl transpeptidase, ferritin, prothrombin-time (PT), international normalized ratio (INR), Total/Direct Bilirubin, Albumin, uric acid), lipids profile (total cholesterol, triglycerides, HDL, LDL) and diabetes biomarkers (insulin, glucose, HbA1c).
    2. Blood tests of adiponectin (only at baseline and 48 weeks after surgery).
    3. Fibroscan test for quantifying liver fibrosis by means of elastography (only at baseline and 48 weeks after surgery).
    4. A blood test (FibroMax) for determining the stage and grade of liver damage (only at baseline and at 24 and 48 weeks after surgery).
    5. OWLiver® test (a serum based test that can discriminate NAFLD from steatohepatitis using metabolomics) at baseline and 48 weeks after surgery.


Secondary Outcome Measures :
  1. Change of postoperative cardiovascular risk compared to baseline. [ Time Frame: Baseline is defined as three weeks to one month before surgery. Change will be assessed 6-12 months after surgery. ]
    Patients will undergo brachial artery flow-mediated dilation (FMD) test (surrogate marker for endothelial function and cardiovascular risk).

  2. Change in cholecystokinin levels before and after the surgery. [ Time Frame: Baseline levels of cholecystokinin at 1-2 days before surgery compared to 8-12 days after surgery. ]
    In addition, gastric cholecystokinin levels will be measured from the removed stomach tissue.


Biospecimen Retention:   Samples With DNA
Whole blood, Liver tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
26 diabetic patients with NAFLD (diagnosed by ultra sound) undergoing sleeve gastrectomy (SG) at Surgery C department at Sheba Medical Center, Israel.
Criteria

Inclusion Criteria:

  • 20≤ age ≤80
  • BMI>35kg/m2
  • Men and women
  • Fatty infiltration in liver ultrasonography

Exclusion Criteria:

  • Alcohol drinking > 140g/week
  • Presence of hepatitis B or C or HIV
  • Known liver disease such as:

    1. Wilson's disease
    2. hemochromatosis
    3. α1-antitrypsin deficiency
    4. autoimmune liver disease
    5. primary biliary cirrhosis
    6. primary sclerosing cholangitis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828528


Locations
Israel
Liver Disease Center, Sheba Medical Center, Tel-Hashomer
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Ziv Ben-Ari, Prof Director Liver Disease Center, Sheba Medical Center, Tel-Hashomer, Israel

Responsible Party: Sheba Medical Center
ClinicalTrials.gov Identifier: NCT01828528     History of Changes
Other Study ID Numbers: SHEBA-12-0026-ZB-CTIL
First Posted: April 10, 2013    Key Record Dates
Last Update Posted: November 28, 2016
Last Verified: November 2016

Keywords provided by Sheba Medical Center:
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Obesity
Bariatric surgery
Weight loss

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases